Details of Disease

General Information of Disease (ID: DISSJR1P)

• Disease Name: Androgenetic alopecia
• Synonyms: androgenic alopecia; male pattern baldness; alopecia androgenetica, male pattern baldness; androgenetic alopecia
• Disease Hierarchy:
  DIS9CG29: Endocrine alopecia
  DIS37HU4: Alopecia
  DISSJR1P: Androgenetic alopecia
• Disease Identifiers:
  MONDO ID: MONDO_0005339
  MESH ID: D000505
  UMLS CUI: C0162311
  MedGen ID: 56404
  SNOMED CT ID: 201144006

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 21 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCC2	TTFLHJV	Limited	Biomarker	[1]
AGXT	TTF5NVW	Limited	Biomarker	[2]
DKK2	TTST5KX	Limited	Genetic Variation	[3]
FAF1	TTSKL3G	Limited	Genetic Variation	[4]
HDAC9	TT8M4E1	Limited	Genetic Variation	[4]
MAPT	TTS87KH	Limited	Genetic Variation	[4]
MTHFR	TTQWOU1	Limited	Biomarker	[1]
OPHN1	TTU7HRD	Limited	Genetic Variation	[4]
PRKAR1A	TTNAHEX	Limited	Biomarker	[5]
RUNX1	TTWIN3H	Limited	Genetic Variation	[4]
SRD5A2	TTT02K8	moderate	Genetic Variation	[3]
VDR	TTK59TV	moderate	Biomarker	[6]
BRD4	TTSRAOU	Strong	Biomarker	[7]
CRH	TTA7YIZ	Strong	Biomarker	[8]
KLK3	TTS78AZ	Strong	Biomarker	[9]
NCOA4	TT8OY02	Strong	Biomarker	[10]
OTC	TT5KIO9	Strong	Biomarker	[11]
PARP1	TTVDSZ0	Strong	Biomarker	[12]
RHOA	TTP2U16	Strong	Biomarker	[13]
SRD5A1	TTTU72V	Strong	Genetic Variation	[14]
TNFRSF10A	TT5WLRX	Strong	Biomarker	[15]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC14A2	DT8QC7K	Limited	Genetic Variation	[4]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AKR1C4	DEAJN47	Limited	Biomarker	[16]
DHRS9	DEGTU5I	Limited	Biomarker	[16]

This Disease Is Related to 26 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ARL17B	OTXZD3DG	Limited	Genetic Variation	[4]
DPY30	OTLHCJ6C	Limited	Genetic Variation	[4]
EBF1	OTZ61YYH	Limited	Genetic Variation	[4]
EDAR	OT3W2UQS	Limited	Genetic Variation	[3]
EIF3E	OTI0WG98	Limited	Genetic Variation	[4]
EMC2	OT3S2TWF	Limited	Genetic Variation	[4]
FAM53B	OTVD7OU6	Limited	Genetic Variation	[4]
FGF5	OTQXGHBY	Limited	Genetic Variation	[4]
GORAB	OTP65YD7	Limited	Genetic Variation	[4]
IRF4	OT1DHQ1P	Limited	Genetic Variation	[4]
KANSL1	OTYNSNNZ	Limited	Genetic Variation	[3]
KLF15	OTGMQMVR	Limited	Genetic Variation	[4]
LRMDA	OTIPNKTU	Limited	Genetic Variation	[4]
MKLN1	OTHMIMH6	Limited	Genetic Variation	[4]
MRPS22	OTIVNAJL	Limited	Genetic Variation	[4]
RSPO2	OT3HHXU0	Limited	Genetic Variation	[4]
SPPL2C	OTUTY2ED	Limited	Genetic Variation	[17]
SSPN	OTYG2SL7	Limited	Genetic Variation	[4]
TBX15	OTAZ9QDX	Limited	Genetic Variation	[4]
TGFB1I1	OTIK337D	Limited	Biomarker	[18]
THADA	OTYZQX0F	Limited	Genetic Variation	[3]
CARD14	OTADQHOV	moderate	Biomarker	[19]
HR	OTHEZWPW	moderate	Biomarker	[20]
AGA	OTNWT1WB	Strong	Biomarker	[21]
COL17A1	OTID5AH2	Strong	Biomarker	[22]
SUPV3L1	OT416O2G	Strong	Biomarker	[23]

References

• [1] Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):572-9.
• [2] Blastic transformation after splenectomy in a patient with nonvillous splenic marginal zone lymphoma with p53 overexpression: a case report.Int J Hematol. 2005 Jun;81(5):417-20. doi: 10.1532/ijh97.05017.
• [3] Detection and interpretation of shared genetic influences on 42 human traits.Nat Genet. 2016 Jul;48(7):709-17. doi: 10.1038/ng.3570. Epub 2016 May 16.
• [4] GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk.Nat Commun. 2017 Nov 17;8(1):1584. doi: 10.1038/s41467-017-01490-8.
• [5] PKA signaling drives reticularis differentiation and sexually dimorphic adrenal cortex renewal.JCI Insight. 2018 Jan 25;3(2):e98394. doi: 10.1172/jci.insight.98394. eCollection 2018 Jan 25.
• [6] Hairless modulates ligand-dependent activation of the vitamin D receptor-retinoid X receptor heterodimer.Biol Pharm Bull. 2012;35(4):582-7. doi: 10.1248/bpb.35.582.
• [7] Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition.Cell Rep. 2014 Sep 25;8(6):1919-1929. doi: 10.1016/j.celrep.2014.08.025. Epub 2014 Sep 18.
• [8] CRF receptor antagonist astressin-B reverses and prevents alopecia in CRF over-expressing mice.PLoS One. 2011 Feb 16;6(2):e16377. doi: 10.1371/journal.pone.0016377.
• [9] Serum androgens and prostate-specific antigen levels in androgenetic alopecia: is there a difference between frontal and vertex baldness?.J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1815-1818. doi: 10.1111/jdv.14758. Epub 2018 Jan 12.
• [10] Expression of androgen receptor coactivator ARA70/ELE1 in androgenic alopecia.J Cutan Pathol. 2005 Sep;32(8):567-71. doi: 10.1111/j.0303-6987.2005.00397.x.
• [11] Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients.Dermatol Ther. 2018 Nov;31(6):e12741. doi: 10.1111/dth.12741. Epub 2018 Oct 8.
• [12] Inflammatory and age-related pathologies in mice with ectopic expression of human PARP-1.Mech Ageing Dev. 2010 Jun;131(6):389-404. doi: 10.1016/j.mad.2010.05.005. Epub 2010 Jun 8.
• [13] Postzygotic inactivating mutations of RHOA cause a mosaic neuroectodermal syndrome.Nat Genet. 2019 Oct;51(10):1438-1441. doi: 10.1038/s41588-019-0498-4. Epub 2019 Sep 30.
• [14] Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia.J Dermatol Sci. 2003 Apr;31(2):135-41. doi: 10.1016/s0923-1811(02)00145-7.
• [15] Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.J Clin Oncol. 2009 Sep 10;27(26):4413-21. doi: 10.1200/JCO.2008.21.7422. Epub 2009 Aug 3.
• [16] Sulforaphane promotes murine hair growth by accelerating the degradation of dihydrotestosterone.Biochem Biophys Res Commun. 2016 Mar 25;472(1):250-4. doi: 10.1016/j.bbrc.2016.02.099. Epub 2016 Feb 26.
• [17] Six novel susceptibility Loci for early-onset androgenetic alopecia and their unexpected association with common diseases.PLoS Genet. 2012 May;8(5):e1002746. doi: 10.1371/journal.pgen.1002746. Epub 2012 May 31.
• [18] Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla.J Dermatol Sci. 2011 Jan;61(1):1-6. doi: 10.1016/j.jdermsci.2010.10.015. Epub 2010 Nov 3.
• [19] Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia.J Vis Exp. 2018 Jan 27;(131):56406. doi: 10.3791/56406.
• [20] A novel missense mutation in the mouse hairless gene causes irreversible hair loss: genetic and molecular analyses of Hr m1Enu.Genomics. 2006 Apr;87(4):520-6. doi: 10.1016/j.ygeno.2005.12.005. Epub 2006 Feb 7.
• [21] Evidence for two independent functional variants for androgenetic alopecia around the androgen receptor gene.Exp Dermatol. 2010 Nov;19(11):1026-8. doi: 10.1111/j.1600-0625.2010.01132.x. Epub 2010 Sep 7.
• [22] Expression of anti-aging type-XVII collagen (COL17A1/BP180) in hair follicle-associated pluripotent (HAP) stem cells during differentiation.Tissue Cell. 2019 Aug;59:33-38. doi: 10.1016/j.tice.2019.06.001. Epub 2019 Jun 21.
• [23] Disruption of Supv3L1 damages the skin and causes sarcopenia, loss of fat, and death.Mamm Genome. 2009 Feb;20(2):92-108. doi: 10.1007/s00335-008-9168-z. Epub 2009 Jan 15.